Pirtobrutinib + Acalabrutinib
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Lymphocytic Leukemia
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Timeline
Jun 30, 2025 → Jul 29, 2030
NCT ID
NCT06839872About Pirtobrutinib + Acalabrutinib
Pirtobrutinib + Acalabrutinib is a phase 2 stage product being developed by Eli Lilly for Chronic Lymphocytic Leukemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06839872. Target conditions include Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06839872 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Chronic Lymphocytic Leukemia